Beone Medicines Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Beone Medicines Ltd (ONC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Beone Medicines Ltd vs Its Competitors
- TTM: Trailing 12-month revenue of 6,606M vs 441,103M combined for its competitors (1.5% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+14.4% annualized vs trailing 12 months), vs accelerating (+8.3%) for its tracked peer group.
- Growth: Beone Medicines Ltd generated 33.9% revenue growth year over year in Q3 2026, vs 14.5% for its competitors combined.
- Profitability: Its 20.4% net margin compares with 19.4% for the peer group.
- Scale: Beone Medicines Ltd ranks #16 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.9% of industry market cap.
- Peer revenue share: Beone Medicines Ltd accounted for 1.6% of combined revenue among its tracked peer group, up from 1.3% a year earlier.
- Peer differentiation: Revenue per employee of $0.55M compares with $1.01M for the peer group (0.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ONC Sales vs. its Competitors, Q3 2026
Beone Medicines Ltd reported revenue growth of 33.86 % year on year in Q3 2026, above its competitors' combined revenue growth of 14.54 %.
With a net margin of 20.36 %, Beone Medicines Ltd achieved higher profitability than its competitors (19.37 %).
Beone Medicines Ltd generated 1.56 % of the combined sales of its peer group, up from 1.34 % a year earlier.
API endpoints for this dataset
Beone Medicines Ltd vs. its Competitors, Q3 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Beone Medicines Ltd reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Beone Medicines Ltd and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Beone Medicines Ltd | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (11) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (7) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Beone Medicines Ltd's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 33.9% for Beone Medicines Ltd. Beone Medicines Ltd's share of combined industry revenue moved from 0.29% to 0.36%, a gain of 0.07 percentage points.
Beone Medicines Ltd's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Beone Medicines Ltd | Yes | Yes | Yes | No |
| Competitors combined (156) | ||||
| High-Confidence Competitors (16) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 85.70 % (6 of 7) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ONC Stock Performance relative to its Competitors
ONC Stock Performance relative to High-Confidence Competitors
ONC Stock Performance relative to Similar-Size Competitors
ONC Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Gt Biopharma Inc | 282.9% | Outperformed |
| 2 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
| 3 | Spyre Therapeutics Inc | 282.9% | Outperformed |
| 4 | Gossamer Bio Inc | 282.9% | Outperformed |
| 5 | An2 Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Beone Medicines Ltd's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Beone Medicines Ltd's Comment on Competition and Industry Peers
Publicly Traded Peers of Beone Medicines Ltd
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Beone Medicines Ltd |
47,972.67 | 6,606.28 |
 Eli Lilly And Company |
1,284,200.05 | 86,462.00 |
 Akari Therapeutics Plc |
884,739.75 | - |
 Johnson and Johnson |
686,611.93 | 99,335.00 |
 Abbvie Inc |
522,704.56 | 66,014.00 |
 Merck and Co Inc |
363,559.30 | 66,569.00 |
| SUBTOTAL | 5,720,057.33 | 736,767.92 |
Sign in to see all competitors of Beone Medicines Ltd .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Beone Medicines Ltd versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Beone Medicines Ltd's Competitors Named by the Company
Competitive relationships identified from Beone Medicines Ltd reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Nurix Therapeutics Inc | Company report | 85% |
| AstraZeneca | Company report | 85% |
| AbbVie & Janssen | Company report | 85% |
| Innocare | Company report | 85% |
| Bristol Meyers Squibb | Company report | 85% |
| Roche | Company report | 85% |
| Merck | Company report | 85% |
| Eli Lilly | Company report | 85% |
| Regeneron | Company report | 85% |
| Akeso | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Nextcure Inc | Company report | 85% |
| Bicara Therapeutics Inc | Company report | 85% |
| Gossamer Bio Inc | Company report | 85% |
| Aptose Biosciences Inc | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Viracta Therapeutics Inc | Company report | 85% |
| Deciphera Pharmaceuticals Inc | Company report | 85% |
| Protara Therapeutics Inc | Company report | 85% |
| Allarity Therapeutics Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Beone Medicines Ltd's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Beone Medicines Ltd's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Beone Medicines Ltd .
Beone Medicines Ltd's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Beone Medicines Ltd | 47,973 | 550,523 | 76,298 |
| Eli Lilly And Company | 1,284,200 | 1,729,240 | 551,594 |
| Akari Therapeutics Plc | 884,740 | - | -4,674,667 |
| Johnson and Johnson | 686,612 | 705,504 | 114,311 |
| Abbvie Inc | 522,705 | 1,158,140 | 181,509 |
| Merck and Co Inc | 363,559 | 887,587 | 42,267 |
| PEERS TOTAL | 5,672,085 | 1,012,620 | 151,601 |
Sign in to see all peers for Beone Medicines Ltd .
Beone Medicines Ltd's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Beone Medicines Ltd | United States 54.39 % |
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Beone Medicines Ltd .
Beone Medicines Ltd's Position in Industry Market Structure
Market-capitalization share and concentration across all 491 companies in Beone Medicines Ltd's industry classification, broader than the peer set above. Market cap in millions of $.Beone Medicines Ltd ranks #16 of 491 companies by market capitalization in its industry, holding 0.90 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 987, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,284,631 | 24.00 % |
| 2 | Johnson and Johnson | 684,228 | 12.78 % |
| 3 | Abbvie Inc | 522,410 | 9.76 % |
| 4 | Merck and Co Inc | 363,559 | 6.79 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 16 | Beone Medicines Ltd | 47,973 | 0.90 % |
Market cap and industry share for the rest of Beone Medicines Ltd's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-11.
Beone Medicines Ltd's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 11 | Bristol myers Squibb Company | 128,840 | 30.72 % |
| 12 | Sanofi | 118,712 | -5.79 % |
| 13 | Gsk Plc | 104,160 | 6.27 % |
| 14 | Regeneron Pharmaceuticals Inc | 101,697 | 38.64 % |
| 15 | Teva Pharmaceutical Industries Limited | 1,234 | 12.3% |
| 16 | Beone Medicines Ltd | 47,973 | 27.56 % |
| 17 | Royalty Pharma Plc | 1,234 | 12.3% |
| 18 | Spyre Therapeutics Inc | 1,234 | 12.3% |
| 19 | Zoetis Inc | 1,234 | 12.3% |
| 20 | Takeda Pharmaceutical Company Limited | 1,234 | 12.3% |
| 21 | Roivant Sciences Ltd | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Beone Medicines Ltd's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-11. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Beone Medicines Ltd's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (447 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 89.39 % | 38.09 % (avg) | +51.3 pp |
| Operating Margin | 17.84 % | industry median | +8.4 pp |
| EBITDA Margin | 20.69 % | -6.73 % (avg) | +27.4 pp |
| Capital Intensity (Capex / Revenue) | 2.13 % | 7.49 % (avg) | -5.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Beone Medicines Ltd's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (447 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 43.6x | 26.3x | +17.3x |
| EV / EBITDA | 26.4x | 15.1x | +11.2x |
| P/B | 8.0x | 4.2x | +3.7x |
| Return on Equity | 18.21 % | industry aggregate | -4.03 % |
| Return on Invested Capital | 9.84 % | -9.73 % (avg) | 19.57 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Beone Medicines Ltd's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | 116.03 % | -27.87 % | 280.83 % | 20.37 % | 73.65 % | 54.90 % | 40.26 % |
| Operating Margin | -356.05 % | -224.16 % | -536.69 % | -122.31 % | -126.40 % | -49.12 % | - | 8.37 % |
| Return on Invested Capital | -20.69 % | -31.32 % | -22.11 % | -15.28 % | -16.40 % | -14.82 % | - | 5.06 % |
| P/E | - | - | - | - | - | - | - | 129.6x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Beone Medicines Ltd's Strategic Group Map
Beone Medicines Ltd is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Beone Medicines Ltd's trailing-12-month revenue growth of 32.9% and operating margin of 17.8% compares with an average of 31.4% growth and 16.2% margin across its 8 closest peers by combined growth, margin and ROIC -- Beone Medicines Ltd sits above that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Beone Medicines Ltd's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Beone Medicines Ltd falls in the Dog quadrant: relative market share of 0.04x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Beone Medicines Ltd's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 987 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.13 % vs industry average 7.49 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Beone Medicines Ltd's dedicated Suppliers and Customers pages, not here.
Beone Medicines Ltd's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Beone Medicines Ltd falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Beone Medicines Ltd's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 8.4 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+14.4% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Low relative market share vs the industry leader (0.04x).
Opportunities
- A meaningful share of competitors (48.70 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Beone Medicines Ltd's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Beone Medicines Ltd | 2.58 | 3.50 | 0.21 |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Akari Therapeutics Plc | 0.23 | 0.26 | 0.04 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
Sign in to see all peers for Beone Medicines Ltd .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Beone Medicines Ltd's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Beone Medicines Ltd | Q3 2026 | +33.9 % | +208.2 % |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| PEERS TOTAL | +10.7 % | +6.7 % |
Sign in to see all peers for Beone Medicines Ltd .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Beone Medicines Ltd's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Beone Medicines Ltd | Q3 2026 | +10.7 % | -26.8 % |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
Sign in to see all peers for Beone Medicines Ltd .
Beone Medicines Ltd's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Beone Medicines Ltd | 10.23% | 13.17% | 18.21% |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Akari Therapeutics Plc | - | - | - |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
Sign in to see all peers for Beone Medicines Ltd .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Beone Medicines Ltd's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Beone Medicines Ltd | 53.81 | 7.26 |
| Eli Lilly And Company | 46.67 | 14.85 |
| Akari Therapeutics Plc | - | - |
| Johnson and Johnson | 42.42 | 6.91 |
| Abbvie Inc | 50.77 | 7.92 |
| Merck and Co Inc | 118.70 | 5.46 |
| PEERS AVERAGE | 51.89 | 7.76 |
Sign in to see all peers for Beone Medicines Ltd .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.